Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D).

NCT02320318 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT02320318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02320318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D).
Lead sponsor
Menarini Group
Phase
Phase 3
Overall status
Withdrawn
Start date
October 31, 2015
Completion date
December 31, 2016
Enrollment
0 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea